Does Insurance Cover Wegovy? How to Check and Appeal a Denial
Coverage depends on your plan: 67% of large employers cover GLP-1s for weight management, but only 13 state Medicaid programs do, and 26 of 300 ACA carriers. Most plans require prior authorization, and denials can be appealed.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Whether insurance covers Wegovy depends almost entirely on what kind of plan you have. Many private and employer plans cover it when you meet the plan’s criteria, and most of those plans require prior authorization before they will pay [5]. Medicaid programs can choose whether to cover weight-loss drugs at all, and Medicare is prohibited under current law from covering obesity drugs through Part D — though new programs are changing what Medicare patients can get starting July 1, 2026 [4][5].
Coverage is also shrinking in some places and holding steady in others. Among large employers, 67% cover GLP-1s for weight management, but only 72% of those say they are likely to continue in 2027 [1]. On the ACA marketplace, just 26 of 300 carriers offer plans covering GLP-1s for obesity [3]. And in Medicaid, 13 states cover GLP-1s for obesity as of January 2026, down from 16 in October 2025 [4].
How many employer plans cover GLP-1s for weight loss?
Two 2026 employer surveys measured coverage, but they asked different questions of different groups, so their numbers are not directly comparable. A Business Group on Health survey of 105 large employer members, completed in February–March 2026, found 67% cover GLP-1s for weight management [1]. Of those employers, 72% said they are likely to continue that coverage in 2027, while 10% said they likely would not [1].
An IFEBP pulse survey of almost 300 US employer health plans, conducted in June 2026, found 36% cover GLP-1s for both diabetes and weight loss — the same percentage as 2025 and up from 34% in 2024 [2]. Meanwhile, 60% cover GLP-1s for diabetes only, up from 55% in 2025, and roughly 45% cover them for other approved conditions such as obstructive sleep apnea and heart disease [2]. About 9% of employers are considering adding obesity coverage [2].
Cost is the reason. GLP-1s accounted for 11.4% of annual claims in 2026, up from 6.9% in 2023, according to IFEBP respondents [2]. Nearly eight in 10 employers say GLP-1s are driving their health care cost increases [1], and 79% report increased utilization of obesity medications [6].
Do ACA marketplace plans cover Wegovy?
Very few. An analysis by Leverage|Axiaci, funded by the Robert Wood Johnson Foundation, reviewed all 300 carriers offering marketplace plans in 2026 and found only 26 cover GLP-1s for treating obesity [3].
Nine states have marketplace plans that cover GLP-1s for obesity: California, North Dakota, New York, Vermont, Pennsylvania, West Virginia, Rhode Island, Delaware, and Georgia. In California and North Dakota, all carriers offer plans that cover them [3].
The coverage that exists comes with strict conditions. All but four carriers limit coverage to people with a BMI of 40 or above, and all carriers require documentation of participation in a diet and exercise program for three to nine months before the request, plus proof that the enrollee was unable to lose weight [3]. Marketplace GLP-1 weight-loss coverage has declined from 3.6 million enrollees in 2024 to 2.8 million in 2026, and the analysis projects that if the 24.5 million people enrolled in ACA plans in 2025 were re-enrolled in 2026, fewer than 10% would have coverage [3].
Does Medicaid cover Wegovy in my state?
Federal law lets states decide. Medicaid programs must cover GLP-1s for diabetes, cardiovascular disease (Wegovy, approved for that use in March 2024), and obstructive sleep apnea (Zepbound, approved December 2024), but coverage for weight loss itself is optional [4].
As of January 2026, 13 state Medicaid programs cover GLP-1s for obesity under fee-for-service, according to KFF [4]. That is down from 16 states as of October 2025: California, New Hampshire, Pennsylvania, and South Carolina have eliminated coverage. North Carolina dropped coverage in October 2025 due to a budget stalemate but reinstated it in December 2025 [4]. When a state does cover GLP-1s for obesity, they are typically subject to prior authorization [4]. Coverage is also required for children when medically necessary under Medicaid’s EPSDT benefit [4].
A federal model may change this picture. The BALANCE model, announced by CMS in December 2025, is a five-year voluntary program that negotiates lower GLP-1 prices and includes standardized coverage criteria. State Medicaid programs and manufacturers were asked to submit participation intentions by January 8, 2026, with the model expected to begin in May 2026 [4].
Does Medicare pay for Wegovy?
For weight loss alone, Medicare Part D coverage of obesity drugs is prohibited under current law [4]. Two new programs are changing what Medicare patients can access, though neither is ordinary Part D coverage of an obesity drug:
- The Medicare GLP-1 Bridge Program: eligible patients pay $50 per month for Wegovy, with the program available nationwide beginning July 1, 2026. It covers all doses and formulations of Wegovy injection and pill for weight management through the end of 2027. Terms apply: eligibility criteria will be determined by CMS, the program applies to eligible Medicare patients prescribed Wegovy for a covered FDA-approved indication, and NovoCare states this information is not a guarantee of coverage [5].
- A short-term Part D demonstration allows Medicare Part D enrollees to access obesity drugs beginning in July 2026 [4].
Separately, Wegovy is covered under normal Part D benefits when prescribed for other FDA-approved uses, including reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease who also have obesity or overweight [5].
How do I check if my plan covers Wegovy?
The fastest route is NovoCare’s online check-coverage form. Most people get results in minutes, and no insurance card is needed. The form asks for the patient’s name, date of birth, ZIP code, which product is being prescribed (pill, pen, or HD pen), and the prescriber’s name and state [5]. There is also a support line at 1-888-809-3942, Monday through Friday, 8:00 am to 8:00 pm ET [5].
One limitation: there is currently no insurance coverage available for Wegovy injection 7.2 mg (the HD pen) — it is self-pay only [5].
When you look at your plan’s formulary yourself, check for Wegovy or semaglutide by name, note the tier it sits on, and look for flags for prior authorization, step therapy, or quantity limits [5].
What does prior authorization for Wegovy typically require?
Among employers that cover GLP-1s for obesity, 90% require prior authorization, 54% require participation in a weight-management program, and 48% require a particular BMI threshold and/or comorbidities beyond the FDA indication [6]. Employers also use strategies like validating clinical eligibility with objective biometric data and limiting prescribing to specific providers [1].
PA requests can take up to 10 business days, so it helps to have your doctor’s office submit the request as soon as the prescription is written [5]. Once approved, a PA can be valid anywhere from 30 days to over a year depending on the plan [5].
Most denials trace back to documentation gaps, according to appeal-service company Honest Care: BMI not documented or not recent, no comorbidity documentation, missing weight-management history, no medical necessity letter, wrong ICD-10 codes, the wrong PA form, or missing labs such as A1C, lipids, or TSH [7]. Honest Care suggests a BMI measured within the last 30 to 90 days [7].
What do I do if my Wegovy claim is denied?
Denials generally fall into five categories: medical necessity, step therapy, formulary exclusion, BMI criteria, and lifestyle documentation [7]. The appeal process has firm deadlines — Honest Care cites 180 days from the denial date to file an internal appeal, a 180-day window for external review, and a decision timeline of 30 to 60 days [7].
Your doctor can file an appeal or request a peer-to-peer review with the insurer [5]. If you have employer-sponsored insurance, your doctor can also send a formal coverage request letter to your HR department, and Novo provides a sample letter for this purpose [5].
A strong medical necessity letter, per Honest Care, should cover comorbidity risks, past lifestyle attempts, prior medication failures or intolerance, and supporting clinical trial evidence such as the STEP and SELECT trials [7]. Honest Care claims that over 65% of PA appeals succeed, but that figure comes from the vendor itself and has not been independently verified [7].
Can I get covered under the heart-disease or liver-disease indication instead?
Sometimes. When a plan excludes weight-loss drugs, coverage may still be available under Wegovy’s other FDA-approved uses, depending on your diagnosis and your plan’s rules. The SELECT trial showed Wegovy reduced major cardiovascular events by 20% in adults with obesity and established heart disease [7], and the FDA approved Wegovy for cardiovascular risk reduction in March 2024 [4].
There is also a liver pathway. The FDA approved Wegovy for MASH (metabolic dysfunction-associated steatohepatitis) in August 2025. In the ESSENCE trial, 63% of patients on Wegovy had MASH resolution versus 34% on placebo, with the indication relevant for fibrosis stages F2–F3 [7].
Whether either pathway applies is a question for your prescriber, since coverage depends on your diagnosis and your plan’s rules.
What is CVS Caremark’s formulary position on Wegovy?
As of July 2025, CVS Caremark moved Wegovy to preferred status on its largest commercial formularies while removing Zepbound [7]. If your pharmacy benefit manager is CVS Caremark, Wegovy may have better coverage than other GLP-1s. Wegovy and Zepbound are different molecules — semaglutide and tirzepatide, respectively — so formulary placement of one does not mean the other is covered.
What does Wegovy cost without insurance?
If coverage is denied or unavailable, Novo Nordisk offers manufacturer self-pay and savings-program prices. These are not list prices, and they require filling through NovoCare Pharmacy (CoAssist Pharmacy d/b/a NovoCare Pharmacy) or using the savings offer, which you can enroll in online or by texting SAVE to 83757 [5].
| Product and dose | Manufacturer self-pay price |
|---|---|
| Wegovy pill, 1.5 mg | $149 per month [5] |
| Wegovy pill, 4 mg | $199 per month [5] |
| Wegovy pill, 9 mg and 25 mg | $299 per month [5] |
| Wegovy pen (new patients, limited time) | $199 per month [5] |
| Wegovy HD pen (new patients) | $399 per month [5] |
One month is defined as one bottle of 30 tablets for the pill [5]. Honest Care cites $199 per month introductory pricing for new patients, then $349 per month self-pay, for the pen [7]. With commercial (non-government) insurance, a copay could be as low as $25 per month through the savings offer [5]. A TrumpRx direct-purchase website also launched after a November 2025 deal between the Trump administration, Eli Lilly, and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and direct buyers [4].
Are there employer workarounds if my plan excludes weight-loss drugs?
Some employers steer workers toward alternatives. About 27% encourage obtaining GLP-1s through a direct-to-consumer platform, and 21% push the use of FSA, HSA, or integrated HRA dollars for the treatments [2]. Employers also offer other benefits: 74% provide disease and chronic care management, 61% provide nutritional counseling, and 61% offer bariatric surgery [2].
If your employer does cover GLP-1s, cost-sharing is often standard: 83% of employers use the same cost-share arrangement for GLP-1s as they do for other medications [1].
What does the coverage trend mean for my timing?
Employers project a median health care cost trend of 9% for 2026, falling to 7.6% after plan design changes, with pharmacy trend projected at 12% [6]. And 87% of employers expect the availability of an oral GLP-1 to raise demand, while only 9% expect a price decrease [1].
The practical takeaway: coverage that exists today may not exist next year. Of employers covering GLP-1s for weight management, only 72% said they were likely to continue in 2027 [1], and companies that do not cover them today are unlikely to add coverage [1]. If your plan currently covers Wegovy, it is worth confirming the terms at each open enrollment.
Sources
- Business Group on Health. GLP-1 costs loom large for employers, forcing challenging coverage decisions, Business Group on Health survey finds.
- CNBC. Employers aren’t expanding coverage of GLP-1 obesity drugs: survey. July 8, 2026.
- Becker’s Payer Issues. GLP-1 coverage under ACA plans continues to decline: 6 notes. December 2, 2025.
- KFF. Medicaid coverage of and spending on GLP-1s. January 16, 2026.
- NovoCare. Check your coverage for Wegovy (semaglutide).
- Business Group on Health. 2026 Employer Health Care Strategy Survey: Executive Summary.
- Honest Care. How to appeal a Wegovy denial: 5 steps + free appeal letter (2026).
- Medical News Today. Appealing Wegovy denial: Prior authorization, letters, and tips.
- Mercer. GLP-1 considerations for 2026: Your questions answered.
- Managed Healthcare Executive. CVS Caremark to place Wegovy as preferred GLP-1 for weight loss. May 1, 2025.
- CVS Health. CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options. May 28, 2026.
- MassHealth. MassHealth changes to management of anti-obesity medications. March 12, 2026.
- The Boston Globe. MassHealth drops GLP-1 coverage for obesity. July 2, 2026.
Frequently asked questions
Does Wegovy need prior authorization, and how long does it take?
Most plans require prior authorization for Wegovy. Among employers covering GLP-1s for obesity, 90% require it. Requests can take up to 10 business days, so ask your doctor's office to submit the PA as soon as the prescription is written. Once approved, a PA can last anywhere from 30 days to over a year depending on your plan.
How long do I have to appeal a Wegovy denial?
Honest Care, an appeal-service company, cites 180 days from the denial date to file an internal appeal, a 180-day window for external review, and a decision timeline of 30 to 60 days. Your doctor can file the appeal or request a peer-to-peer review with the insurer.
Does Medicare pay for Wegovy for weight loss?
Medicare Part D coverage of obesity drugs is prohibited under current law. However, the Medicare GLP-1 Bridge Program offers eligible patients Wegovy for $50 per month nationwide beginning July 1, 2026, covering all doses and formulations for weight management through the end of 2027. Terms apply: CMS determines eligibility, the prescription must be for a covered FDA-approved indication, and the program is not a guarantee of coverage. Wegovy is also covered under normal Part D for other FDA-approved uses, such as cardiovascular risk reduction.
Does Medicaid cover Wegovy in my state?
As of January 2026, 13 state Medicaid programs cover GLP-1s for obesity under fee-for-service, down from 16 in October 2025 after California, New Hampshire, Pennsylvania, and South Carolina eliminated coverage. States must cover Wegovy for its cardiovascular indication, and coverage is required for children when medically necessary under EPSDT.
Do ACA marketplace plans cover Wegovy?
Rarely. Of the 300 carriers offering 2026 marketplace plans, only 26 cover GLP-1s for obesity, across nine states. All but four carriers limit coverage to a BMI of 40 or above, and all require documented diet and exercise program participation for three to nine months plus proof of failed weight loss.
What BMI do insurers require for Wegovy?
It varies by plan. Among employers covering GLP-1s for obesity, 48% require a particular BMI threshold and/or comorbidities beyond the FDA indication. On ACA marketplace plans, all but four carriers limit GLP-1 coverage to a BMI of 40 or above. Honest Care suggests documentation of a BMI measured within the last 30 to 90 days.
What can I do if my plan excludes weight-loss drugs entirely?
Two alternative coverage pathways exist. Wegovy is FDA-approved for cardiovascular risk reduction in adults with established cardiovascular disease plus obesity or overweight, and for MASH, a form of fatty liver disease, approved in August 2025. Your doctor can also send a formal coverage request letter to your HR department if you have employer-sponsored insurance.
Can I get covered under the heart-disease or liver-disease indication instead?
Possibly. The SELECT trial showed a 20% reduction in major cardiovascular events in adults with obesity and established heart disease, and Wegovy was FDA-approved for that use in March 2024. For MASH, the ESSENCE trial showed 63% MASH resolution versus 34% on placebo, relevant for fibrosis stages F2–F3. Whether these apply depends on your diagnosis and plan rules.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.